There are two types of benzodiazepine receptors in the mammalian brain. Central benzodiazepine receptors (CBR) are exclusive to neuronal membranes, where they associate with the GABA a receptor complex and mediate the anxiolytic and anti-convulsive properties of benzodiazepines (Möhler and Okada, 1977; Tallman and Gallager, 1985) . The peripheral benzodiazepine receptor (PBR) differs from the central-type in anatomic and subcellular distribution as well as pharmacology and function. Compared to the brain, the PBR is more abundant in peripheral organs, including the lungs, adrenal glands, liver, kidneys, blood cells, testis, and placenta (Gavish et al., 1992; Woods and Williams, 1996; Zisterer and Williams, 1997) . High levels are also found in some extra-neuronal tissues such as the choroid plexus and ependymal cells of the ventricles (Richards and Möhler, 1984) . Subcellular-fractionation studies have demonstrated an association with the outer mitochondrial membrane (Anholt et al., 1986; Antkiewicz-Michaluk et al., 1988; Hirsch et al., 1988), although recent evidence suggests a small number of receptors may be localized in the plasma membrane of certain peripheral organs (Woods and Williams, 1996) . The PBR appears to facilitate the transport of cholesterol from the outer to the inner mitochondrial membrane, the rate-determining step of steroidogenesis (Papadopoulos, 1998; Papadopoulos and Brown, 1995) . It has also been implicated in other cellular processes, including growth and differentiation and the immune response (Zisterer and Williams, 1997) .
There are two types of benzodiazepine receptors in the mammalian brain. Central benzodiazepine receptors (CBR) are exclusive to neuronal membranes, where they associate with the GABA a receptor complex and mediate the anxiolytic and anti-convulsive properties of benzodiazepines (Möhler and Okada, 1977; Tallman and Gallager, 1985) . The peripheral benzodiazepine receptor (PBR) differs from the central-type in anatomic and subcellular distribution as well as pharmacology and function. Compared to the brain, the PBR is more abundant in peripheral organs, including the lungs, adrenal glands, liver, kidneys, blood cells, testis, and placenta (Gavish et al., 1992; Woods and Williams, 1996; Zisterer and Williams, 1997) . High levels are also found in some extra-neuronal tissues such as the choroid plexus and ependymal cells of the ventricles (Richards and Möhler, 1984) . Subcellular-fractionation studies have demonstrated an association with the outer mitochondrial membrane (Anholt et al., 1986; Antkiewicz-Michaluk et al., 1988; Hirsch et al., 1988) , although recent evidence suggests a small number of receptors may be localized in the plasma membrane of certain peripheral organs (Woods and Williams, 1996) . The PBR appears to facilitate the transport of cholesterol from the outer to the inner mitochondrial membrane, the rate-determining step of steroidogenesis (Papadopoulos, 1998; Papadopoulos and Brown, 1995) . It has also been implicated in other cellular processes, including growth and differentiation and the immune response (Zisterer and Williams, 1997) .
Pharmacological differences between the two receptors were identified by comparing the binding of clonazepam, a prototypic CBR ligand, with the non-tranquilizing benzodiazepine Ro 5-4864, specific for the PBR (Richards and Möhler, 1984) . The PBR has been characterized by radioligand-binding assays and receptor autoradiography, using [ 3 H]-Ro 5-4864 and the isoquinoline carboxamide [ 3 H]-PK11195 (Awad and Gavish, 1987; Benavides et al., 1983; Le Fur et al., 1983) . Although both ligands exhibit nanomolar affinity for rodent PBR, Ro 5-4864 has relatively low affinity for the PBR in some other species including humans Gavish, 1987, 1991; Doble et al., 1987) . Additionally, PK11195 has greater selectivity for the PBR than Ro 5-4864, making [ 3 H]-PK11195 the preferred ligand in most published studies.
The PBR has been proposed as a general marker of gliosis in the nervous system because of its exclusive localization to glial cells (Benavides et al., 1990; Richards and Möhler, 1984) . The binding of [ 3 H]-PK11195 is dramatically increased in the brains of experimental animals following ischemic (Benavides et al., 1990; Myers et al., 1991; Stephenson et al., 1995) , physical (Banati et al., 1997; Gehlert et al., 1997; Miyazawa et al., 1995) , and chemical damage (Altar and Baudry, 1990; Benavides et al., 1987; Bendotti et al., 1994; Guilarte et al., 1995; Kuhlmann and Guilarte, 1997) as well as in some neurodegenerative diseases (Diorio et al., 1991; Mesßmer and Reynolds, 1998; Owen et al., 1983; Vowinckel et al., 1997) . Increased PBR expression follows a similar pattern to other glial marker proteins, such as glial fibrillary acidic protein (GFAP), a marker for astrocytes, and the CR3 complement receptor, a microglial marker (Banati et al., 1997; O'Callaghan et al., 1990a,b; Stephenson et al., 1995) . Since astrocytosis and microglial activation are hallmark responses of the central nervous system to injury, these findings support the use of the PBR as an indicator of gliosis.
In order for the PBR response to be a useful indicator of neurotoxicity, it must be able to detect subtle forms of neuronal damage such as nerve terminal degeneration. The goal of the present study was to characterize the spatial, temporal, and dose-related response of the PBR to systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration. Nervous system damage resulting from exposure to this dopaminergic neurotoxicant provides a unique opportunity to investigate the PBR response to two distinct types of neuronal pathologies. That is, MPTP causes degeneration of dopaminergic cell bodies in the substantia nigra pars compacta (SNc) as well as degeneration of axonal terminals projecting to the corpus striatum (Heikkila et al., 1989) . The loss of dopaminergic terminals in the corpus striatum occurs in the absence of neuronal loss intrinsic to that structure. The results from the present study demonstrate that the PBR response is sensitive in detecting both the subtle damage associated with dopaminergic axonal terminal degeneration and the cell body loss occurring in brain structures vulnerable to MPTP neurotoxicity.
MATERIALS AND METHODS
Animal model. Adult male C57Bl/6 mice (Charles River, Wilmington, MA) weighing 20 -25 g were used in this study. This strain of mice was selected because it exhibits a pattern of degeneration of midbrain dopaminergic nuclei, which most closely resembles that observed in Parkinson's disease (German et al., 1996; Sundström et al., 1987) . Groups of mice received a total of 10, 20, 40, 60, or 80 mg/kg MPTP (Research Biochemicals, Inc., Natick, MA) or saline vehicle. Doses were split into four equal subcutaneous injections given at 2-h intervals. Mice were euthanized by decapitation at 24 h, 3, 7, or 21 days following the final MPTP injection. Brains were quickly removed from the skull, rinsed in ice-cold saline, immediately frozen on dry ice and stored at Ϫ80°C.
Quantitative receptor autoradiography. Mouse brains were cut into 20 m horizontal sections on a freezing microtome (Ϫ25°C), thaw-mounted on poly-L-lysine-coated microscope slides, and stored at Ϫ20°C. Prior to autoradiography, brain sections were dried for 20 min at 37°C. [ 3 H]-PK11195 autoradiography was performed to visualize PBR expression, as previously described (Kuhlmann and Guilarte, 1997) . Briefly, slides were washed for 5 min and incubated in 50 mM Tris-HCl (pH ϭ 7.4) with 1 nM [ 3 H]-PK11195 (85.5 Ci/mmol; New England Nuclear, Wilmington, DE) for 30 min at 25°C. The binding reaction was terminated by two 5-s washes in ice-cold buffer followed by two 5-s washes in cold deionized water. Non-specific binding was assessed in adjacent sections by adding a final concentration of 10 M unlabeled PK11195 (Research Biochemicals, Inc. (Sidman et al., 1971) . Dorsal striatum was defined at the level of the habenular nucleus corresponding to horizontal section number 77 in the mouse brain atlas. Ventral striatum was defined at the level of the substantia nigra corresponding to horizontal section number 137.
[ 3 H]-PK11195 saturation isotherms. Striata from four mice (60 mg/kg MPTP or saline vehicle; 7 days post injection) were combined and homogenized in 150 vol. of 50 mM Tris-HCl (pH ϭ 7.4 at 4°C) and centrifuged at 40,000 g for 30 min. The resulting pellet was resuspended in buffer and used for the radioligand-binding assay. Total binding of [ 3 H]-PK11195 was determined for concentrations ranging from 0.1 to 15 nM. Non-specific binding was assessed for each concentration in the presence of 10 M unlabeled [
3 H]-PK11195. The binding reactions were incubated for 60 min at 4°C in a total volume of 500 l. The reaction was terminated by vacuum filtration through GF/B filters, followed by 3 washes with 5 ml of ice-cold buffer. Radioactivity trapped in the filters was measured by liquid scintillation spectrometry. Protein concentration of the tissue homogenates was determined by the method of Lowry et al. (1951) . Binding parameters were estimated using the EBDA/ LIGAND program for the Macintosh (Biosoft).
Determination of striatal dopamine concentrations by HPLC with electrochemical detection. Dopamine levels in the corpus striatum of control and MPTP-treated mice were measured as described by Guilarte et al. (1987) , with some modifications. Mouse striata were homogenized in 10 volumes of 0.1 M perchloric acid containing dihydroxybenzylamine (DHBA; 1 ng/20 l) as an internal standard. Homogenates were centrifuged at 7,400 g for 15 min, and the resulting supernatant was filtered by centrifugation through 0.22 m nitrocellulose filters (Bioanalytical Systems, West Lafayette, IN) at 1000 g for 10 min. Twenty microliters of the filtered supernatant was separated on a C18 ODS reverse-phase column (Bioanalytical Systems), using a mobile phase of 50 mM phosphate buffer, 10 mM trisodium citric acid, 100 mg/L EDTA, 125 mg/L sodium octyl sulfate and 4% acetonitrile (pH ϭ 3.2) at a flow rate of 1.0 ml/min. Dopamine levels were measured with a BAS LC-4B electrochemical detector. Duplicate determinations were performed for all homogenates (n ϭ 4 -6 for all treatment groups).
Tyrosine hydroxylase immunohistochemistry. For immunohistochemical studies, mice (n ϭ 3-6 per treatment group) were deeply anesthetized with urethane (1.5 g/kg) and sacrificed by transcardiac perfusion of 0.1 M phosphate buffer (pH ϭ 7.4) followed by a buffered solution of 4% paraformaldehyde containing 0.05% gluteraldehyde. The brains were removed and post-fixed overnight at 4°C in a buffered paraformaldehyde solution, then transferred to 20% sucrose for at least 48 h. The brains were then frozen in dry ice-cooled isopentane, sectioned in the coronal plane on a freezing microtome (20 m), mounted, and stored at Ϫ80°C. Sections were thawed, washed, and incubated with 1% hydrogen peroxide in buffer for 30 min. This was followed by blocking with 5% normal goat serum (Zymed, San Francisco, CA) and incubating at room temperature for one h in a rabbit anti-tyrosine hydroxylase polyclonal antibody (1:1000, Eugene Tech Int., Ridgefield, NJ). Immunoreactivity was visualized using an avidin-biotin-HRP complex (ABC Elite, Vector Laboratories) with 3,3Ј-diaminobenzidine as the chromogen. Tyrosine hydroxylase-positive cells of the substantia nigra pars compacta were counted by light microscopy. Duplicate determinations of each animal were done in sections separated by 40 m.
Statistics. Multiple mean comparisons within a time point were done by one-way analysis of variance (ANOVA) followed by Duncan's New Multiple Range Post-hoc Test, where significance was indicated. Temporal data was initially compared using a two-way ANOVA with MPTP-dose and time-afterinjection as the two main effects. If an interaction was indicated, mean comparisons were done within time points for a specific MPTP dose by one-way ANOVA. There was no statistical difference between control animals in autoradiographic results over time. Thus, control results from all time points were pooled (n ϭ 23). Correlation of the PBR response with dopaminergic markers was done by simple linear regression, followed by a two-tailed Student's t-test to determine if the slope differed significantly from zero.
RESULTS

Characterization of Nigrostriatal Dopaminergic Lesion following MPTP Administration
The integrity of nigrostriatal dopaminergic terminals innervating the corpus striatum from cell bodies located in the substantia nigra was assessed by two different methods. The dopamine level in the corpus striatum was used as a neurochemical index, and the quantitative receptor autoradiography of the high affinity dopamine transporter (DAT) selective ligand, [ 3 H]-WIN 35,428, was used as an anatomical index of presynaptic dopaminergic terminal integrity (Fig. 1) . In an attempt to find a threshold of MPTP neurotoxicity, dopamine (Table 1) and DAT levels ( Fig. 2) were measured in the striatum 7 days after MPTP doses ranging from 10 to 80 mg/kg. This dosing regimen was used to span a wide range of neuronal damage. Dopamine and DAT levels in the corpus striatum were reduced by more than 95% seven days after the 80-mg/kg MPTP dosage, the highest dose used (Table 1, Fig.  2) . A small but significant reduction (13%; p Ͻ 0.05) in striatal dopamine content was measured following the 10-mg/kg MPTP dosage, the lowest tested (Table 1) . This dose also resulted in a modest reduction of DAT levels in the ventral, but not the dorsal, striatum (Fig. 2) . Tyrosine hydroxylase (TH) immunohistochemistry was used to visualize and count nigrostriatal dopaminergic cell bodies in the substantia nigra pars compacta (SNc) (Fig. 3) . Dose-dependent reductions in the number of TH-positive cells in the SNc were measured 7 days after administration of 40, 60, or 80 mg/kg MPTP (Table 1) , the highest dose, and a 67% reduction was noted.
The temporal aspect of MPTP-induced damage in the corpus striatum was assessed using [
3 H]-WIN 35,428 autoradiography, following doses of 40 or 60 mg/kg MPTP. Two-way ANOVA indicated significant dose (dorsal, F 2,49 ϭ 80, p ϭ 0.0001; ventral, F 2,49 ϭ 414; p ϭ 0.0001), time (dorsal, F 3,49 ϭ 93, p ϭ 0.0001; ventral, F 3,49 ϭ 7.7, p ϭ 0.0003) and dose ϫ time (dorsal, F 6,49 ϭ 2.3, p ϭ 0.05; ventral, F 6,4 9 ϭ 5.0, p ϭ 0.0004) effects in the striatum. Striatal DAT levels were significantly reduced (p Ͻ 0.01) as early as 24 h after MPTP administration (Fig. 4) . In the dorsal striatum of mice treated with 40 or 60 mg/kg MPTP, the largest reduction in DAT levels was measured at 3 days after injection. From this time, there was a partial recovery of DAT levels by 21 days in the 40 mg/kg MPTP group only (Fig. 4) . A similar pattern was also present in the ventral striatum, except that maximal reductions of DAT levels were measured at 1 and 3 days after injection of 40 or 60 mg/kg MPTP, respectively (Fig. 4) . A small but significant (p Ͻ 0.01) recovery of DAT levels was measured in the ventral striatum of mice injected with 40 or 60 mg/kg MPTP by 21 days after injection (Fig. 4) .
Peripheral Benzodiazepine Receptor Expression following MPTP Administration
Quantitative autoradiography of [ 3 H]-PK11195 was used to measure PBR levels in adjacent brain sections to those used for   FIG. 3 . Representative coronal sections of the rostral midbrain, immunostained for tyrosine hydroxylase 7 days after MPTP exposure. Total MPTP doses are given in parentheses (mg/kg). Abbreviations: SNc ϭ substantia nigra pars compacta; SNr ϭ substantia nigra pars reticulata; PBP ϭ nucleus parabrachialis pigmentosus; fr ϭ fasciculus retroflexus.
FIG. 4. Time-course of MPTP-induced loss of high affinity dopamine transporter measured by [
3 H]-WIN 35,428 quantitative autoradiography. Values are expressed as mean Ϯ sem (n ϭ 4 -6 for MPTP treatment groups; **p Ͻ 0.01 compared to controls).
DAT determinations (Fig. 5) . PBR expression in the dorsal striatum at the level of the habenular nuclei was significantly (p Ͻ 0.01) elevated 24 h after administration of MPTP doses as low as 40 mg/kg (Fig. 6A) . The magnitude of the PBR response was not diminished 21 days after injection of either 40 or 60 mg/kg MPTP (Fig. 6A) . A different pattern of PBR expression was observed in the ventral striatum at the level of the substantia nigra (Fig. 6B ). An equally robust increase was measured by 24 h, with levels peaking at 3-7 days, followed by a decline to control levels by 21 days (Fig. 6b) . PBR levels in the substantia nigra were also significantly elevated (p Ͻ 0.01) 24 h after MPTP exposure, and a reduction in the response occurred over time (Fig. 6C) . PBR levels returned to control values by 21 days after exposure to 40 mg/kg MPTP, but remained elevated in mice treated with 60 mg/kg (Fig. 6C) .
Dose-dependent increases of [ 3 H]-PK11195 binding were measured throughout the vulnerable nigrostriatal pathway 7 days after MPTP treatment (Table 2) . A maximal PBR response was measured at doses as low as 20 and 40 mg/kg MPTP in the dorsal and ventral striatum, respectively, whereas the PBR response in the SNc increased in a dose-dependent manner up to 80 mg/kg. Small but significant increases in PBR levels were also measured in other brain structures, but only at the highest doses of MPTP ( 3 H]-PK11195 binding was a result of an increase in the apparent number of binding sites [Bmax: control ϭ 1159 Ϯ 66 fmol/mg protein (n ϭ3); MPTP ϭ 1697 Ϯ 161 fmol/mg protein (n ϭ 4); p Ͻ 0.05], with no change in receptor affinity (Kd: control ϭ 1.14 Ϯ 0.21 nM; MPTP ϭ 1.11 Ϯ 0.13 nM; p Ͼ 0.05).
Correlation of the PBR Response with Lesion Severity
Peripheral benzodiazepine receptor expression was correlated with indexes of dopaminergic terminal degeneration in the corpus striatum and cell body loss in the SNc 7 days after MPTP administration. This time point was selected because it exhibits a maximal PBR response. PBR levels in the corpus striatum measured by [ 3 H]-PK11195 binding were inversely associated with reductions in striatal dopamine content ( Fig.  7a; (Fig. 7C) .
DISCUSSION
The present study examined the PBR response to discrete lesions of the nigrostriatal dopaminergic pathway resulting from administration of the neurotoxicant MPTP. The regional and temporal expression of neuronal degeneration following MPTP administration has been extensively characterized in a number of animal species. In C57Bl/6 mice, systemic MPTP administration produces a rapid and selective loss of dopaminergic neuronal cell bodies in the SNc and degeneration of axonal terminals innervating the corpus striatum (German et al., 1996; Heikkila et al., 1984 Heikkila et al., , 1989 Sundström et al., 1987) .
Characterization of dopamine and DAT levels in the corpus striatum was performed 7 days after the administration of 10 -80 mg/kg MPTP. The loss of striatal dopaminergic markers appeared to be a more sensitive index of MPTP neurotoxicity than the loss of TH-positive cell bodies in the SNc. There was a 95% loss of both dopamine content and minergic cell bodies in the SNc was measured. These findings are consistent with a retrograde mechanism of neurotoxicity where axonal degeneration precedes and is more extensive than neuronal cell body loss (Herkenham et al., 1991; Imai et al., 1988) . Temporal characterization of dopaminergic terminal degeneration showed that DAT levels in the corpus striatum were reduced as early as 24 h after injection of 40 or 60 mg/kg MPTP (Fig. 6) . A small but significant recovery of [ 3 H]-WIN 35,428 binding was measured 21 days after both doses of MPTP (Fig 4) . This finding is consistent with studies by Sundström et al. (1987) in which a small recovery of dopamine levels in the corpus striatum was measured 5 weeks after MPTP. The recovery of DAT levels may represent either an upregulation of DAT in the remaining dopaminergic terminals or a process of reinnervation by the surviving dopaminergic neurons.
A dorso-ventral gradient of sensitivity to MPTP neurotoxicity was apparent within the corpus striatum. Levels of DAT were reduced to a greater extent and at lower MPTP doses in the ventral compared to the dorsal striatum (Figs. 2, 4 ). This observation is consistent with the immunohistochemical findings of Sundström et al. (1988) , who demonstrated increasing dopaminergic terminal loss along the dorso-ventral axis 7 days after MPTP exposure. Further, Sundström et al. (1988) reported that a medial-lateral and rostral-caudal gradient of sensitivity to MPTP exists within the SNc. Axonal projections from these differentially sensitive cells may contribute to the differential pattern of DAT loss and recovery.
Peripheral benzodiazepine-receptor expression in the brain of MPTP-treated mice was measured using [ 3 H]-PK11195 quantitative autoradiography. Dose-dependent increases in [ 3 H]-PK11195 binding were measured in the corpus striatum and SNc, the primary targets of MPTP neurotoxicity (Table 2) . At the highest MPTP dose used, increased [ 3 H]-PK11195 binding was also measured in other brain structures such as the septal nucleus, frontal cortex, and inferior colliculus. This response may be associated with MPTP-induced degeneration of serotonergic and/or noradrenergic synaptic terminals, since MPTP is known to affect these monoaminergic systems at higher doses than needed to induce dopaminergic neurotoxicity (Sundström et al., 1987) . The PBR response at 7 days after MPTP administration showed a highly significant correlation with both markers of striatal dopaminergic terminal integrity (Figs. 7A,B) . A significant correlation was also found between (Fig. 7C ). These findings demonstrate that the PBR is a sensitive biomarker for detecting not only neuronal cell body loss but also the more subtle pathology associated with axonal terminal degeneration.
The temporal pattern of PBR expression was assessed in the corpus striatum and SNc following 40 or 60 mg/kg MPTP injections (Fig. 6 ). In the dorsal striatum, there was a rapid and maximal increase in [
3 H]-PK11195 binding by 24 h, which remained until 21 days, the last time point examined. In the ventral striatum and the SNc, a rapid increase in [
3 H]-PK11195 binding was also measured at 24 h, but peak levels were not achieved until 3 days after injection. The PBR response was attenuated by 21 days, returning to control levels in the 40 mg/kg MPTP group. These findings suggest that, like dopaminergic terminal loss, a gradient of the PBR response to MPTP neurotoxicity exists within the striatum.
A dorso-ventral gradient in the astrocytic response to MPTP administration has been demonstrated in the corpus striatum (Francis et al., 1995) . GFAP immunoreactivity in normal striatum was largely confined to processes of periventricular astrocytes in the dorsomedial region. By 24 h after MPTP treatment, immunoreactivity increased in the dorsal striatum with little change in ventral regions. However, by 48 h, increased GFAP immunostaining was present in both dorsal and ventral striatum, with the dorsal striatum expressing a greater number of cells and more intense GFAP immunoreactivity. The increase in GFAP immunostaining subsided considerably by 6 weeks. The transient nature of the astrocytic response in the corpus striatum of MPTP-treated mice has also been measured using GFA protein and GFAP mRNA levels (O'Callaghan et al., 1998) . Other studies assessing the microglial response to MPTP neurotoxicity in the corpus striatum and SNc also demonstrate a rapid but transient microgial response, which subsides 14 -21 days after MPTP administration (Czlonkowska et al., 1996; Kohutnicka et al., 1998) . Since the PBR is known to be expressed in both astrocytes and microglia (Benavides et al., 1990) , and its response to MPTP neurotoxicity follows a pattern similar to other glial markers, it appears that the PBR is a good indicator of reactive gliosis. The present work and previous studies assessing the PBR response to brain damage resulting from chemical exposures (Guilarte et al., 1995; Kuhlmann and Guilarte, 1997) suggest that the PBR response is associated with the onset, degree, and duration of damage. When damage progresses over days or weeks, there is a protracted response of glial marker proteins including the PBR (O'Callaghan, 1993; Guilarte et al., 1995) . With subtle damage, such as that present in the corpus striatum of MPTPtreated mice, the glial response appears to be shorter in duration.
An important finding of the present study is that PBR expression 7 days after injection of 10 mg/kg MPTP was not increased in the corpus striatum (Table 2) , despite small but significant reductions of both DAT levels and dopamine content (Table 1, Fig. 2 ). This suggests either that the PBR response to this small degree of terminal degeneration was resolved 7 days after exposure, or that the damage was below the threshold necessary to trigger a response. Alternatively, it is possible that a small but significant PBR response was present but was below the limit of detection. The main limitations of accurately measuring PBR levels in the rodent brain are that receptor levels are low and non-specific [ 3 H]-PK11195 binding accounts for approximately 40% of total binding. Currently, the only commercially available form of PK11195 is a racemic mixture. Recently, Shah et al., (1994) have synthesized the individual enantiomers of PK11195 and demonstrated that the R-enantiomer is retained to a greater extent in lesioned brain tissue than the S-enantiomer. This is consistent with previous studies on the stereoselective nature of the isoquinoline carboxamide binding site (Dubroeucq et al., 1986) . Use of Note. Values are expressed as means Ϯ sem in fmol/mg tissue (*p Ͻ 0.05; **p Ͻ 0.01); n ϭ 4 -6 for MPTP treatment groups; n ϭ 23 for the control group. CS (dor), dorsal corpus striatum; CS (ven), ventral corpus striatum; SN, substantia nigra; Sept. Nuc., septal nucleus; Fr. Ctx., frontal cortex; Inf. Coll., inferior colliculus; CA-1, CA-3/4, hippocampal subfields; Dent. Gyr., dentate gyrus; Cerebell., cerebellum.
the pharmacologically active enantiomer could improve the signal-to-noise ratio of the autoradiograms, increasing the sensitivity and enabling the detection of smaller increases of PBR expression. It is possible that a striatal PBR response could be measured following a 10-mg/kg MPTP dose, if the pharmacologically active R-enantiomer of [ 3 H]-PK11195 is used. This study represents our continuing effort to characterize the PBR as a generalized biomarker of neurotoxicity (Guilarte et al., 1995; Kuhlmann and Guilarte, 1997) . Assessment of the PBR response to different classes of neurotoxicants in rodent models will validate and extend its use to studies of the living brain in humans and non-human primates. To our knowledge, the PBR is the only biomarker of neurotoxicity with the potential for in vivo neurotoxicological studies. Imaging reactive gliosis in living brain following neurotoxicant exposure is now possible, since the PBR selective ligand PK11195 has been labeled with positron ( 11 C) and single photon emitting ( 123 I) radioisotopes. The feasibility of this approach has been demonstrated in clinical studies with a limited number of subjects with gliomas (Junck et al., 1989; Pappata et al., 1991) , stroke (Ramsay et al., 1992) and multiple sclerosis (Vowinckel et al., 1997) using [
11 C]-PK11195 Positron Emission Tomography. Our long-term goal is to assess the PBR as an in vivo biomarker of neurotoxicity following chemical exposures, using brain imaging methodologies.
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FIG. 7.
Correlations between the PBR response in the ventral corpus striatum and (A) reductions of striatal dopamine (r 2 ϭ 0.93) and (B) loss of high affinity dopamine transporter levels indicative of presynaptic terminal integrity (r 2 ϭ 0.84). (C) A highly significant correlation was also measured between the PBR response in the substantia nigra and dopaminergic cell body loss measured by tyrosine hydroxylase immunoreactivity (r 2 ϭ 0.95).
